We sought to determine whether differentiation agents such as retinoids and butyrate regulate transcript levels of interphotoreceptor retinoid binding protein (IRBP) and cone rod homeobox (CRX), a homeodomain transcription factor that regulates IRBP promoter activity. WERI-Rb1 retinoblastoma cells were treated with all-trans retinol, all-trans retinoic acid, or butyrate. IRBP and CRX mRNA levels were determined by quantitative RT-PCR. Butyrate at low concentrations increased both mRNA levels but suppressed them at higher concentrations. Retinoic acid had minimal effects. Retinol increased CRX mRNA over four fold. IRBP and CRX transcript levels are sensitive to butyrate and CRX expression is sensitive to retinol. Ó
Introduction
Interphotoreceptor retinoid binding protein (IRBP) is a large glycolipoprotein that accumulates at high concentration in the interphotoreceptor space (IPS) (BuntMilam & Saari, 1983; Carlson & Bok, 1992; Okajima, Pepperberg, Ripps, Wiggert, & Chader, 1989; Okajima, Pepperberg, Ripps, Wiggert, & Chader, 1990; van Veen et al., 1986) . Though its physiological role remains to be determined, ablation of the IRBP gene leads to progressive visual dysfunction in knock-out mice .
IRBP expression is tightly restricted to photoreceptors of the retina and pinealocytes of the pineal gland in mammals (Liou, Wang, & Matragoon, 1994; van Veen et al., 1986) , though this expression profile may differ in other vertebrates (Stenkamp, Cunningham, Raymond, & Gonzalez-Fernandez, 1998) . Retinoids may regulate IRBP levels. Treatment of retinoid-deprived rodents with retinol increases IRBP immunoreactivity in the IPS and retina (Katz, Gao, & Stientjes, 1993; , though possibly not through transcription regulation . As the proximal IRBP promoter contains a conserved retinoic acid receptor element (RARE) (Boatright, Borst, et al., 1997; Boatright, Nickerson, & Borst, 2000) , regulation could be via activation of retinoic acid receptors (RARs). Retinol can bind RARs (Giguere, Ong, Segui, & Evans, 1987; Petkovich, Brand, Krust, & Chambon, 1987) and retinol can be metabolized to retinoic acid, which also activates RARs (see Ross, McCaffery, Drager, & DeLuca, 2000 for review) . Alternatively, potential regulation could be indirect. Retinoids in some cases regulate terminal differentiation via homeodomain proteins (Ross et al., 2000) ; IRBP promoter activity is regulated by homeodomain proteins such as OTX2, Rx, and CRX (Chen et al., 1997; Furukawa, Morrow, & Cepko, 1997; Bobola et al., 1999; Fong & Fong, 1999; Kimura et al., 2000; .
To determine whether retinoids can affect IRBP mRNA levels, we examined the effects of retinol and retinoic acid on IRBP transcript levels in cultured WERI-Rb1 retinoblastoma cells. We additionally tested the effects of butyrate, another differentiation agent Vision Research 42 (2002) 933-938 www.elsevier.com/locate/visres previously shown to induce IRBP expression in retinoblastoma cells (Kyritsis, Wiggert, Lee, & Chader, 1985) . Transcript levels of CRX, another photoreceptor-specific gene, and GAPDH, a ubiquitously-expressed gene, were monitored also.
Methods
The CAT plasmid vectors used were based on the promoterless CAT vector pBLCAT3 (GenBank Accession number X64409), which served as a negative control. Two IRBP promoter/CAT reporter plasmids, one using a À1783 to þ101 fragment and the other a À156 to þ101 fragment of the murine IRBP sequence (Genbank accession M32734), were constructed as previously described (Boatright, Borst, et al., 1997; Boatright, Buono, et al., 1997) . Both contain a putative RARE at À113 to À110, relative to transcription start.
WERI-Rb1 retinoblastoma cells (HTB-169; ATCC, Manassas, VA) were maintained as previously described Boatright, Knox, et al., 2001) . Cells were plated at 5 Â 10 5 cells per 35 mm culture well in 1 ml of growth medium and transfected with plasmids or treated with drugs the same day. Transfections were via Superfect (Qiagen; Valencia, CA) as previously described Boatright, Knox, et al., 2001) . For drug treatments, all chemicals were purchased from Sigma Chemical Co., St. Louis, MO. All-trans retinol and all-trans retinoic acid were dissolved in 100% ethanol in dim red light and stored at À80°C. Serial dilutions in ethanol were prepared in dim red light immediately prior to addition to cultures. Control cultures received ethanol without retinoids. A 1 M stock solution of n-butyric acid sodium salt was dissolved in Opti-MEM I reduced serum medium (GIBCO-BRL, Grand Island, NY) and serial dilutions of this were prepared in incubation medium immediately prior to addition to cultures. Cells were incubated for 16 h at 37°C in 5% CO 2 following addition of transfection mixtures or drugs to culture media. The decision to use a 16 h incubation was partially based on previous work examining retinoid regulation of homeobox genes (Bang, Papalopulu, Kintner, & Goulding, 1997; Chariot, Moreau, Senterre, Sobel, & Castronovo, 1995; Gaunt, 1991; Houle, Prinos, Iulianella, Bouchard, & Lohnes, 2000; Lindberg, Wunderlich, Dinsmore, & Jacoby, 1998; Simeone et al., 1991; Simeone et al., 1990) .
Cells were assayed for CAT activity as previously described (Boatright, Buono, et al., 1997) . Briefly, cell cytoplasm solutes were mixed with tritiated acetyl-Coenzyme A and chloramphenicol and CAT activity measured as the accumulation of 3 H-acetylchloramphenicol over time. CAT activity is reported as CAT enzyme units Â10 À5 , and represent the mean of 3 repeats AESEM per group per experiment.
Real time reverse transcription PCR (RT-RT-PCR)
was performed on total RNA from cells as previously described ) with exceptions. RNA and primers (see below) were added to Quantitect SYBR Green RT-PCR master mix (QIAGEN Inc., Valencia, CA) as per manufacturer instructions. Reverse transcription, PCR amplification, and fluorescence detection of product were conducted using a Bio-Rad iCycler iQ real time PCR detection system (Bio-Rad, Hercules, CA). Relative mRNA concentrations were estimated based on the number of PCR cycles required to reach a threshold of PCR product fluorescence intensity. The threshold was taken as a value above background corresponding to ten times rms noise of fluorescence intensity across a window usually spanning cycles 2 through 10. For each template RNA, threshold cycle numbers (TCN) for IRBP and CRX reactions were subtracted from TCN of GAPDH reactions to correct for differences in total RNA starting concentration. The effect of treatment on relative mRNA concentration (i.e., the effect on transcript levels) was taken as ð1:95 ðaÀbÞ Þ where a ¼ TCN for no treatment and b ¼ threshold cycle number for treatment. Data are foldchange means AE SEM.
Primers were designed to span introns ) and were as follows (forward then reverse, respectively): GAPDH, 5 0 -GCC AAG GTC ATC CAT GAC AAC-3 0 and 5 0 -GAG GAG TGG GTG TCG CTG TT-3 0 ; IRBP, 5 0 -CAA GGT GCC CAC GGT GCT-3 0 and 5 0 -GGC CAC TGA CCT CAT GTC GAT-3 0 ; CRX, 5 0 -TCA AGA ACC GGA GGG CTA AAT-3 0 and 5 0 -ATA GCT CTG GCC TGA TAG GGA-3 0 ; and opsin, 5 0 -ACC ACA CAG AAG GCA GAG AAG GAG-3 0 and 5 0 -ATG ACA GGG TTG TAG ATG GCG G-3 0 . Numerical data are group means AE standard errors of the mean (SEM). Statistical differences were determined by Student's unpaired t-test or by simple analysis of variance followed by Newman-Keuls post hoc analysis as noted in Results. Experiments were repeated 3-7 times as indicated in legends.
Results
Treatment of retinoblastoma cells with varying concentrations of butyrate had biphasic effects on IRBP and CRX mRNAs levels (Fig. 1) . For IRBP mRNA, treatment with butyrate stimulated mRNA levels, with the effect peaking between 0.05 and 0.2 mM butyrate and producing about a five fold increase over untreated controls (Fig. 1) . Higher concentrations suppressed mRNA below control levels (Fig. 1) . For CRX mRNA, treatment with butyrate stimulated mRNA levels, with the effect peaking at 0.1 mM butyrate and producing about a three fold increase over untreated controls (Fig. 1) . Higher concentrations suppressed mRNA below control levels (Fig. 1) . Even at the highest concentrations tested, butyrate treatment did not alter cell counts, morphology, or protein content of cultures (data not shown).
The effect of retinoic acid on IRBP and CRX mRNA in retinoblastoma cells was minimal and variable (Fig.  2) . Additional experiments testing the effects of retinoic acid at 4, 8, 21, 28, and 48 h of treatment similarly showed no effect on IRBP or CRX transcript levels (data not shown). Testing the effect of retinoic acid treatment on opsin mRNA was precluded because opsin mRNA could not be detected in WERI cells via our RT-RT-PCR assay (data not shown). This is in agreement with previous work demonstrating lack of opsin immunoreactivity in WERI cells (Herman et al., 1989) .
The lack of effect of retinoic acid on IRBP mRNA levels was unexpected. To further assess the effect of retinoic acid on IRBP promoter activity, cells were treated with retinoic acid and transiently transfected with IRBP/CAT promoter plasmid constructs. Treatment with 10 lM retinoic acid (final concentration) had no significant effect on CAT activity (Table 1) . No effect was seen across a 1-100 lM range of retinoic acid concentrations (data not shown).
Contrary to results with retinoic acid, treatment with retinol stimulated CRX mRNA levels with increasing concentration (Fig. 3) . The effect of retinol on IRBP was minimally stimulatory and not statistically significant (Fig. 3) . Treatment with either butyrate or the retinoids had no significant or consistent effect, relative to total RNA concentration or protein content of individual samples, on GAPDH mRNA levels (data not shown).
Discussion
Treatment of WERI-Rb1 retinoblastoma cells with butyrate produced a concentration-dependent biphasic effect on CRX and IRBP transcript levels. To our knowledge, this is the first report of an effect of butyrate or any pharmacological agent on CRX gene expression. As CRX is considered an important regulator of development in the retina (Chen et al., 1997; Furukawa et al., 1997) , it may not be surprising that butyrate, a compound commonly used to induce differentiation, has effects on CRX transcript levels. The effect of butyrate on homeodomain protein expression is relatively unstudied. Butyrate stimulates the expression of Hox1.6 in Fig. 1 . Effect of butyrate on IRBP and CRX mRNA levels retinoblastoma cells were incubated 16 h in the presence of various concentrations of butyrate as indicated. Following incubation, total RNA was isolated and used as template in RT-RT-PCRs with primers specific for GAPDH, IRBP, or CRX. Data represent the fold difference between mRNA estimates (corrected against GAPDH signal) from treated and untreated groups.
Ã P < 0:05 vs respective untreated group. N ¼ 3-5 per data point. CRX data points are squares; IRBP data points are circles. teratocarcinoma F9 cells (Iwai et al., 1995) and PDX-1 in cultured rat pancreatic acini (Rooman, Heremans, Heimberg, & Bouwens, 2000) . Though a likely mechanism of action for butyrate is via histone deactelyase inhibition (Jung, 2001; Riggs, Whittaker, Neumann, & Ingram, 1977) , it is unclear how this mechanism would regulate specific homeodomain transcription factors.
The effect of butyrate on IRBP transcript levels is in partial agreement with that found previously in Y-79 retinoblastoma cells (Kyritsis et al., 1985) . However, the stimulatory effect we find occurred at much lower concentrations of butyrate than in Y-79 cells, whereas the concentrations found to increase IRBP synthesis in Y-79 cells (2-4 mM) (Kyritsis et al., 1985) are inhibitory in WERI cells. The suppressive effect appears to be somewhat specific as no changes were observed in cell counts, gross morphology, or total protein content across culture samples.
Retinol treatment produced a concentration-dependent rise in CRX transcript levels. To our knowledge, this is the first report of effects of retinoids on CRX expression. Conversely, retinoic acid, a biologically active retinol metabolite (Ross et al., 2000) that activates transcription of other retinal genes such as opsin (Picking et al., 1996; Sun, Chen, Harrelson, & Stark, 1993) and arrestin (Wagner et al., 1997) , had little effect on either IRBP or CRX transcript levels (Fig. 2) . Because of this surprising result, we tested whether retinoic acid treatment stimulates IRBP promoter activity. Using a transient transfection assay with which we have much experience, we found that retinoic acid had no effect on reporter gene activity driven by two different IRBP promoter fragments, both containing putative RAREs (Table 1) . It is unusual for retinol to have an effect while retinoic acid has none, but it is perhaps not surprising that retinol, a retinoid of central importance to the visual cycle, may affect the transcription of photoresponsive genes; such a regulatory mechanism might be expected to be unique to the photoreceptor cell.
The relative effects of the two retinoids resemble those found in dispersed chicken retina cell cultures, where retinol much more potently induced differentiation than retinoic acid, and did so without first being metabolized into retinoic acid (Stenkamp, Gregory, & Adler, 1993) . The authors of that work postulated that retinol may have direct effects on photoreceptor progenitor cells, possibly by binding an as-yet unidentified retinol-selective retinoid nuclear receptor (Stenkamp et al., 1993) . The data presented here are not at variance with that working hypothesis. Alternatively, it has been suggested that retinol may act as a photoreceptor-specific survival factor (Fuhrmann, Heller, Rohrer, & Hofmann, 1998) . Increased survival of CRX-expressing cells could underlie the quadrupling effect of retinol on CRX transcript levels, though its lack of effect on cell density and IRBP transcript level do not support this explanation.
The minimal effects of retinol on IRBP mRNA levels may suggest a non-CRX mediated pathway to control IRBP transcript levels. Though treatment with butyrate causes a somewhat parallel change in the transcript levels of the two genes, the large stimulatory effect of retinol on CRX mRNA level was not mimicked in IRBP mRNA level. It may be that other homeobox proteins regulate IRBP endogenously (Kimura et al., 2000; Livesey, Furukawa, Steffen, Church, & Cepko, 2000; Bobola et al., 1999; Briata et al., 1999; Fong & Fong, 1999) . Alternatively, the current data may simply indicate that the homeobox consensus element in the IRBP promoter is fully occupied with endogenous transcription factors in WERI cells, as suggested by CRX overexpression experiments (Zhu & Craft, 2000) . If either condition exists, increases in CRX levels would not be expected to dramatically increase IRBP expression.
Butyrate and retinoid treatment had no effect on GAPDH mRNA level, allowing its use as a normalizaton factor in analyzing the effects of treatments on CRX and IRBP mRNA levels. That these compounds had no effect on a constitutively active gene while altering transcript levels of genes associated with various states of photoreceptor differentiation may underscore their potential use as differentiation agents in retinal gene studies.
These experiments contribute to studies of CRX and IRBP gene expression by identifying two pharmacological tools, butyrate and retinol, that robustly affect IRBP and CRX mRNA levels. There is an unexpected Fig. 3 . Effect of retinol on IRBP and CRX mRNA levels retinoblastoma cells were incubated 16 h in the presence of various concentrations of all-trans retinol as indicated. Following incubation, total RNA was isolated and used as template in RT-RT-PCRs with primers specific for GAPDH, IRBP, or CRX. Data represent the fold difference between mRNA estimates (corrected against GAPDH signal) from treated and untreated groups.
Ã P < 0:05 vs respective untreated group. N ¼ 3-7 per data point. CRX data points are squares; IRBP data points are circles.
selectivity for the action of the two retinoids in regards to CRX, with retinol active and retinoic acid inactive. Interestingly, the stimulatory effect of retinol on CRX mRNA level is specific in that little effect is seen on another retina-selective gene, IRBP. Thus, retinol might be a useful tool for manipulating CRX expression, particularly in conjunction with other pharmacological manipulations that suppress CRX expression . As mRNA amounts are altered, the regulation provided by retinol or butyrate may be at the level of transcription or mRNA degradation.
